NCT04460443 is a Phase 2, PHASE3 clinical trial of sofosbuvir in COVID, sponsored by Tanta University.

Who is sponsoring NCT04460443?

NCT04460443 is sponsored by Tanta University.

What drugs are being tested in NCT04460443?

Interventions in NCT04460443: sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir.

Is NCT04460443 still recruiting?

NCT04460443 is currently status unknown. Last updated 8 December 2020.

Last reviewed 2020-12-08 · How we verify

NCT04460443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sofosbuvir in Treatment of COVID 19

Status unknown Phase 2, PHASE3 Last updated 8 December 2020

What this trial tests

Phase 2, PHASE3 trial testing sofosbuvir in COVID in 60 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
1 August 2021

31 August 2021

Quick facts

Lead sponsor	Tanta University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 August 2020
Primary completion	1 August 2021
Estimated completion	31 August 2021
Sites	1 location across Egypt

Drugs / interventions tested

sofosbuvir — full drug profile →
Sofosbuvir ledipsavir — full drug profile →
Daclatasvir (DACLATASVIR) — full drug profile →

Conditions studied

COVID — all drugs for COVID →

Sponsor

Tanta University

Who can join

Eligibility, any sex, with COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19: Characteristics and Therapeutics.
Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
Vicenti I, Zazzi M, Saladini F. · · 2021 · cited 77× · PMID 33475441 · DOI 10.1080/13543776.2021.1880568
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.
Li X, Peng T. · · 2021 · cited 25× · PMID 34017257 · DOI 10.3389/fphar.2021.660710
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial.
Abbass S, Kamal E, Salama M, Salman T, et al · · 2021 · cited 18× · PMID 34379337 · DOI 10.1002/jmv.27264
A Comprehensive Summary of the Knowledge on COVID-19 Treatment.
Peng Y, Tao H, Satyanarayanan SK, Jin K, et al · · 2021 · cited 18× · PMID 33532135 · DOI 10.14336/ad.2020.1124
How to use COVID-19 antiviral drugs in patients with chronic kidney disease.
Kale A, Shelke V, Dagar N, Anders HJ, et al · · 2023 · cited 14× · PMID 36843922 · DOI 10.3389/fphar.2023.1053814

Verify or expand the search:

Other trials of sofosbuvir

Trials testing the same drug.

NCT02768961 — Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) · Phase 4 · completed
NCT02717949 — Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study · Phase 4 · terminated

Other recruiting trials for COVID

Currently open trials in the same condition.

NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04460443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 8 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04460443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing